Enigma Biomedical USA, Inc. Announces a Collaboration to Apply Novel 4R PET Imaging Biomarkers to CTE Research
Enigma Biomedical USA, Inc. (EB USA) today announced that it is starting a collaboration with the Boston University Chronic Traumatic Encephalopathy (CTE) Center and the Concussion Legacy Foundation. This collaboration will focus on demonstrating the value of 4R Tau PET imaging biomarkers in advancing our understanding of CTE.
Enigma Biomedical USA, Inc. Announces Candidate Selection of Novel 4R Tau PET Imaging Biomarkers
Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA executed an Exclusive License and Option Agreement (License) with AbbVie for the development and potential commercialization of AbbVie’s next-generation F18 PET imaging biomarkers to assess the presence of 4R Tau in subjects with suspected neurodegenerative disease. These imaging biomarkers hold great promise as important new tools in advancing understanding of a range of neurodegenerative diseases in which the misfolded 4R Tau protein is implicated, including the tauopathies Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration.
Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04
On January 16, 2025, Neuraly Inc. (Neuraly), a wholly owned subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. (Enigma) announced the signing of a research license and commercialization option agreement for PMI04, a PET (Positron Emission Tomography) imaging biomarker of neuroinflammation developed by Neuraly.
